---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-23-000026"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T01:25:03.254669+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q1 revenue $134.3M (+17% YoY); net loss $50.7M; raises FY2023 guidance to $590-$610M

## Summary
- Revenue $134.3M (+17% YoY); spatial portfolio drove growth, Xenium in first full launch quarter.
- Net loss $50.7M vs $42.4M in prior year; operating loss $52.0M incl $42.1M stock-based comp.
- Gross margin 73% (down from 78%) due to product mix and inventory write-downs.
- Raised FY2023 revenue guidance to $590-610M (prev $580-600M); 14-18% growth.
- Cash and marketable securities $418.3M as of March 31.

## SEC filing metadata
- accession: 0001770787-23-000026
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000026/0001770787-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000026/txg-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-23-000026
- JSON: https://secwatch.observer/filing/0001770787-23-000026.json
- Plain text: https://secwatch.observer/filing/0001770787-23-000026.txt

## Key facts
- Earnings Releases
  10x Genomics, Inc. reported first quarter ended March 31, 2023 results: revenue $134.3 million, net income $50.7 million. Guidance raised.
  - Period: first quarter ended March 31, 2023
  - Revenue: $134.3 million
  - Net income: $50.7 million
  - Guidance: raised
  - Result: reported results
  source text: PLEASANTON, Calif. May 3, 2023 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2023. Recent Highlights • Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022. • Surpassed 5,000 customer publications using 10x Genomics products, demonstrating the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000026/0001770787-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.